VENENUM BIODESIGN was established with the mission of improving patients' lives through the discovery of therapeutic compounds against our novel biological platforms. Our goal is to advance our discoveries to medicine through partnership with pharmaceutical companies.
VENENUM BIODESIGN utilizes state-of-the-art assay development and ultra-high throughput screening (UHTS) against our proprietary 5.5. million ECLiPS compound collection, protein engineering and production, cellular reagent generation, structural biology, medicinal chemistry, and in vitro assays and in vivo models for our own platforms. We offer access to these capabilities, to academic institutions, non-profits, research organizations, and pharmaceutical companies.
VENENUM BIODESIGN is a company within the Genesis Biotechnology Group (GBG) located conveniently in "Einstein's Alley" research corridor in Hamilton, New Jersey (http://www.einsteinsalley.org/), and is easily accessible to other academic medical centers, biotech and pharmaceutical companies in the New York/ New Jersey/ Pennsylvania area.
VENENUM BIODESIGN has collaborative research arrangements with several for-profit and not-for-profit groups and is seeking further relationships.
